Candesartan Aurobindo

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candesartan Aurobindo

What is Candesartan Aurobindo?

Candesartan Aurobindo is a medication belonging to a class of drugs known as angiotensin II receptor antagonists (ARBs). It contains the active substance candesartan cilexetil, which is a prodrug that is converted into the active form, candesartan, after oral administration. This medication is primarily used to manage conditions related to the cardiovascular system.

How it Works

Angiotensin II is a naturally occurring hormone in the body that causes blood vessels to tighten and narrow. By binding to specific receptors, it can lead to an increase in blood pressure and place additional strain on the heart. Candesartan Aurobindo works by blocking these receptors, preventing angiotensin II from exerting its effects. As a result, blood vessels relax and widen, allowing blood to flow more easily and reducing the workload on the heart.

Clinical Uses

This medication is typically prescribed for two main clinical purposes:

  • Hypertension: It is used to treat high blood pressure (hypertension) in adults and children. Lowering blood pressure helps reduce the long-term risk of cardiovascular events.
  • Heart Failure: It may be used in adult patients with heart failure when there is a reduction in heart muscle function. In these cases, it is often used in addition to other treatments or when certain other medications cannot be tolerated.

Candesartan Aurobindo is available in various strengths to allow for flexibility in managing these chronic conditions over time.

Regulatory References

  1. NIH DailyMed for Candesartan Cilexetil
  2. Angiotensin II Receptor Blockers (ARBs) overview

What side effects are possible with Candesartan Aurobindo?

Candesartan cilexetil's safety profile is documented by regulatory authorities, classifying possible adverse reactions by frequency and the body system affected. This framework establishes the official safety boundaries for the medicine.


Official Classification of Adverse Reactions

Side effects are officially classified into frequency tiers based on clinical trial incidence data. Common reactions are those reported in approximately 1 to 10 out of every 100 patients. Very Rare reactions occur in fewer than 1 out of every 10,000 patients.

Frequency Category Examples of Officially Listed Adverse Reactions
Common Upper respiratory tract infection, dizziness, headache, back pain, pharyngitis, and rhinitis.
Very Rare Blood disorders (leukopenia, agranulocytosis), hyperkalemia (high potassium), cough, nausea, abnormal hepatic function, angioedema, rash, and renal impairment or failure.

Critical Safety Considerations

The regulatory label highlights serious adverse reactions and population-specific restrictions. The most critical safety warning concerns Fetal Toxicity: use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus. Immediate discontinuation is required if pregnancy is detected.

Angioedema, a rare but potentially life-threatening swelling of the face, lips, tongue, or throat, is documented as a serious adverse reaction. Additionally, patients with severe hepatic impairment or cholestasis are formally contraindicated from use. Patients with Heart Failure show a higher incidence of discontinuation due to symptomatic hypotension and hyperkalemia.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the officially documented descriptions of overdose and the required emergency actions as stated in regulatory prescribing information.

Documented Manifestations of Overdose

Overdose with Candesartan cilexetil is primarily expected to result in an exaggerated pharmacological effect, with the most likely clinical manifestation being hypotension (severe low blood pressure). Additional documented signs include dizziness and changes in heart rate, specifically either tachycardia (fast heart rate) or, in some cases, bradycardia (slow heart rate).

Required Emergency Actions

Official regulatory guidance mandates that anyone who suspects an overdose must seek immediate medical attention. Additionally, patients are advised to contact a Poison Control Center for prompt guidance. The primary concern in an overdose scenario is the potential for severe symptomatic hypotension, which may require hospitalization and continuous monitoring.

Management and Specific Considerations

Treatment is officially described as symptomatic and supportive. No specific antidote for Candesartan is known or documented in official labeling. For managing severe hypotension, regulatory sources describe procedures such as placing the patient in a supine position and administering intravenous (IV) normal saline infusion to expand blood volume. A key consideration noted in the drug's profile is that Candesartan is highly protein-bound and cannot be removed effectively by hemodialysis.

Therapeutic Uses of Candesartan Aurobindo

What Candesartan Aurobindo Treats: Main Uses and Benefits

Candesartan Aurobindo is commonly used to address symptoms related to heightened physiological activity, and to provide support for symptoms related to systemic imbalance. This medication is used in areas where additional symptomatic support is needed. It is commonly used to help with essential hypertension and may assist with managing symptoms related to chronic heart failure in adults; it is relevant for easing symptoms linked to organ-specific functional stress, such as in cases involving Diabetic Nephropathy.

This medication assists with managing symptoms that create noticeable physiological strain, and contributes to improved day-to-day comfort during symptomatic periods.

“Supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.”


Quick Fact: Relief for Sustained Vascular Strain

Category Description
Relevant Use Management of high blood pressure.
Relevant Use Supportive management of chronic heart failure.
Relevant Use Supports the body in managing risks associated with stroke and heart attack.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Candesartan Aurobindo is determined by official regulatory criteria, primarily based on age, pregnancy status, and coexisting conditions. The medicine is approved for use in adults for both hypertension and heart failure. For children and adolescents, use is approved for hypertension in patients typically 1 to less than 17 years of age, though safety and efficacy are not established for heart failure in this population.

Contraindications and Restrictions

Use is contraindicated and must be avoided in several population groups as defined by official labeling:

Classification Population or Condition
Absolute Prohibition Second and third trimesters of pregnancy.
Absolute Prohibition Infants (children aged below 1 year) for hypertension.
Absolute Prohibition Patients with severe hepatic impairment and/or cholestasis.
Absolute Prohibition Patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m^2) who are also taking Aliskiren-containing products.

Use is not recommended in the first trimester of pregnancy or while breastfeeding. Patients with severe renal impairment or volume depletion require close monitoring and conditional use, reflecting limitations documented in the regulatory prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Angiotensin Converting Enzyme (ACE) Inhibitors; Potassium-sparing diuretics; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Agents that increase serum potassium (e.g., Lithium).
Specific interacting medicines Aliskiren (restricted use); Lithium.
Mechanistic basis of interactions Pharmacodynamic: Dual inhibition of the Renin-Angiotensin System (RAS); Additive effects on potassium retention (hyperkalemia risk); Reduced antihypertensive effect. Pharmacokinetic: Reduced renal clearance of the co-administered drug (specific to Lithium). Metabolic: Absence of clinically significant interaction with the CYP450 enzyme system.
Timing-based interaction rules None documented. Official labeling does not specify mandatory timing separation requirements for co-administration.
Population-specific interaction notes The combination with Aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment. The risk of worsening renal function with NSAIDs is heightened in the elderly, volume-depleted, or those with pre-existing compromised renal function.
Interaction-related restrictions Dual blockade of the RAS using Aliskiren, other ARBs, or ACE inhibitors is generally restricted due to increased risks of hyperkalemia, hypotension, and renal impairment.

The official regulatory profile for Candesartan Aurobindo is primarily structured around pharmacodynamic liabilities related to electrolyte balance and blood pressure control. The documentation notes that co-administration with potassium-sparing agents and salt substitutes containing potassium increases the documented risk of hyperkalemia. Additionally, the label identifies a specific pharmacokinetic interaction with Lithium, which results in increased systemic exposure of Lithium due to reduced renal clearance. Regulatory sources also confirm that the drug is not significantly metabolized by the CYP450 system and that the ingestion of food does not clinically affect its bioavailability.

Mechanism of Action

Candesartan is an angiotensin II receptor blocker (ARB), functioning as a selective, competitive antagonist of the angiotensin II type 1 receptor (AT1). The AT1 receptors are primarily located on vascular smooth muscle, cardiac tissue, and the adrenal cortex. The active metabolite, candesartan, binds with high affinity to the AT1 receptor, preventing the binding of the endogenous agonist, angiotensin II (Ang II). This action blocks the Ang II-mediated G-protein coupling and subsequent activation of the intracellular signaling cascade. Specifically, the inhibition suppresses the activation of phospholipase C and the increase in intracellular calcium ion concentration. The consequence is the blockade of AT1 receptor-driven cellular effects, which include vasoconstriction and the stimulation of aldosterone release. This mechanism results in system-level physiological modulation characterized by peripheral vasodilation and a reduction in aldosterone-mediated sodium and water retention.

Dosage and Administration Information

Candesartan Aurobindo is intended for oral administration and is typically utilized as a tablet, available in strengths from 4 mg to 32 mg. Administration is generally a once-daily use regimen, and the drug may be taken with or without food as the absorption is not significantly affected.

Standard Dosing Regimens

The dosing structure is dependent on the condition being addressed.

  • Adult Hypertension: The standard starting dose is 16 mg once daily, progressing to a total daily dose range of 8 mg to 32 mg. The total daily amount may be administered once or divided into two equal doses.
  • Adult Heart Failure: The initial administration dose is 4 mg once daily. The dose is systematically increased by doubling at intervals of at least two weeks to achieve the 32 mg maximum target dose, as tolerated. The maximal reduction in blood pressure is typically achieved within four to six weeks of treatment.

Special Population and Procedural Rules

No initial dose adjustment is required for older adults (aged 65 years and over) or in cases of mild to moderate hepatic impairment. However, an initial dose of 4 mg may be considered for patients who are volume-depleted or those with severe renal impairment. If a dose is missed, the instruction is to take it as soon as it is recalled, unless it is nearly time for the next scheduled administration, in which case the missed dose must be skipped; double or extra doses must not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Candesartan Aurobindo

The clinical evaluation of Candesartan was studied for its use through formal research, including large-scale randomized controlled trials (RCTs) and long-term observational studies. This overview summarizes the structure and reported findings of this research, focusing on the clinical contexts where the medication was studied.


Evidence for Use in Managing High Blood Pressure

Research exploring Candesartan in high blood pressure involves short-term, placebo-controlled trials primarily measuring changes in systolic and diastolic blood pressure in adults with hypertension. These studies monitored outcomes monitoring physiological strain or stress. Findings describe patterns related to the blood pressure measurements that occurred during the defined study period. However, certainty remains low for long-term cardiovascular event outcomes based on these short-term trials alone.

Evidence for Use in Managing Chronic Heart Failure

Substantial research comes from large-scale, multi-year randomized, double-blind trials designed to study the clinical course of symptomatic heart failure patients with reduced heart pumping ability ( LVEF leq 40%) receiving Candesartan. These studies monitored composite outcomes, including the frequency of hospitalization for heart failure or cardiovascular death. Research highlights changes measured during the study period concerning outcomes related to systemic or functional imbalance. Findings for patients with preserved pumping ability ( LVEF > 40%) were observed to be mixed or less definitive.

Evidence for Use in Managing Symptoms Related to Diabetic Nephropathy

Research in this area was evaluated in patients with Type 2 Diabetes who also had high blood pressure and signs of early kidney involvement. Studies explored how symptoms evolved in the observed populations by primarily measuring a biomarker called the albumin-to-creatinine ratio (ACR). Follow-up durations were limited in many of the trials designed to measure initial biomarker change. Data for long-term outcomes, such as delaying end-stage kidney disease, are still emerging and often rely on measurements of surrogate biomarkers.


What Remains Uncertain About Candesartan Research

Research helps show what has been observed so far, but several areas remain uncertain. Comparative evidence is lacking for certain head-to-head comparisons against all available drug classes for hypertension. Data for specific groups remain insufficient, particularly for pediatric populations, and research related to pregnancy is limited. Furthermore, research does not determine whether an individual will respond similarly to the group patterns described in the trials.

Frequently Asked Questions (FAQ)

Common questions about Candesartan Aurobindo (FAQ)


Q: How quickly can I expect Candesartan Aurobindo to start lowering blood pressure?

Most of the blood pressure-lowering effect is typically observed within two weeks of beginning treatment. The full maximum effect that the medication is expected to achieve is generally reached after approximately four weeks of initial dosing, according to clinical study data.


Q: Can taking Candesartan Aurobindo affect my kidney function?

Official regulatory documents indicate that changes in renal function (kidney function) or renal impairment are documented as a very rare potential adverse reaction. The drug is sometimes used cautiously in patients who already have existing kidney issues or heart failure, as described in its prescribing information.


Q: Will I need to have regular blood tests while on Candesartan Aurobindo?

Official prescribing information advises that serum potassium and renal function should be monitored periodically in certain individuals. This monitoring is generally recommended for patients also taking specific other medications, such as those that might increase potassium levels or certain pain relievers, due to potential associated risks.


Q: Is it safe to drink alcohol while taking Candesartan Aurobindo?

Regulatory sources often note that the medication can occasionally cause dizziness or weariness. Since alcohol can potentially cause or worsen these effects, patients are often advised in authoritative resources to discuss alcohol consumption with a healthcare professional.


Q: Does Candesartan Aurobindo have a known risk for skin cancer or sun sensitivity?

The official adverse reaction lists do include rash and itching as very rare reactions. However, specific risks for general sun sensitivity (photosensitivity) or skin cancer are not documented as common or rare side effects on the primary regulatory labels.


Q: Are there specific symptoms that indicate I should contact a healthcare professional immediately?

Severe reactions such as angioedema (swelling of the face, lips, tongue, or throat) should prompt immediate medical attention. Additionally, the regulatory label strictly states that the medication must be discontinued immediately if pregnancy is detected due to the risk of fetal harm.


Q: Does Candesartan Aurobindo affect cholesterol levels?

Clinical study data included in the official label indicate that during treatment for high blood pressure, there were no clinically significant changes observed in metabolic measures, including levels of total cholesterol, triglycerides, or blood sugar.


Q: What is Candesartan Aurobindo's pregnancy risk classification?

The FDA's previous system placed the drug under Category C for the first three months of pregnancy and Category D for the second and third trimesters. The Category D warning indicates that there is evidence of potential harm to the developing fetus.


Q: Is it safe to breastfeed while taking Candesartan Aurobindo?

The official prescribing documentation states that use is not recommended while breastfeeding, particularly when nursing a newborn or premature infant. This recommendation is due to a lack of available information regarding the presence of candesartan in human breast milk.


Q: Does Candesartan Aurobindo interact with lithium medication?

Yes, official regulatory documents explicitly warn of an interaction with medications containing lithium. This co-administration can lead to increased concentrations of lithium in the blood and a greater risk of lithium toxicity, requiring careful monitoring of lithium levels.


Q: Are there any over-the-counter pain relievers that should not be taken with Candesartan Aurobindo?

The regulatory documents mention Non-Steroidal Anti-Inflammatory Agents (NSAIDs) as a category that can interact with candesartan. Many common over-the-counter pain relievers belong to this class, and they may potentially reduce the blood pressure-lowering effect and increase the risk of worsening kidney function.


Q: How does Candesartan Aurobindo compare to losartan or valsartan?

Studies summarized in the regulatory information indicate that Candesartan (at its maximum labeled dose) was observed to lower both systolic and diastolic blood pressure by a slightly greater amount on average compared to losartan (at its maximum labeled dose) when measured at peak and trough effects.


Q: Can Candesartan Aurobindo be crushed or split if a person has trouble swallowing?

Official product information for Candesartan Cilexetil tablets often notes that they are designed with a score line. The presence of a score line is an official feature that allows the tablet to be divided.


Q: What is the typical elimination half-life of candesartan in the body?

Pharmacokinetic data in the official labeling reports that the elimination half-life of candesartan (the time it takes for half of the drug to be eliminated from the body) is approximately 9 hours.


Q: Does Candesartan Aurobindo have different effects on men and women?

According to the pharmacokinetics data presented in the official regulatory documents, there were no observed differences in how the body processes candesartan between male and female subjects.


Q: Are there specific ethnic groups where the blood pressure-lowering effect may be less pronounced?

Official labeling notes that the effectiveness of Angiotensin II Receptor Blockers (ARBs), including candesartan, is often less pronounced in black patients compared to non-black patients when the medication is taken alone (monotherapy).


Q: Does Candesartan Aurobindo affect fertility?

Authoritative medical sources, citing the drug's official profile, state that there is no evidence to suggest that taking candesartan reduces fertility in either men or women.


Q: Is there research evidence supporting the use of Candesartan for stroke prevention?

The medication is officially indicated for lowering blood pressure. The regulatory text states that achieving this reduction in blood pressure is known to reduce the risk of certain major cardiovascular events, primarily strokes and heart attacks.


Q: How long does Candesartan Aurobindo stay in the body after stopping treatment?

The length of time the medication stays in the body is determined by its half-life, which is approximately 9 hours. It takes about four to five half-lives for the medication to be nearly completely eliminated from the body.


Q: Is there a risk of high potassium levels (hyperkalemia) when taking this drug?

Yes, hyperkalemia (high potassium) is listed as a potential serious adverse reaction. The regulatory label notes that this is a Very Rare side effect in the general patient population but is more frequently seen in patients with heart failure or those taking other drugs that affect potassium levels.


Q: What should I do if I experience an upset stomach after taking the tablet?

Official patient information notes that nausea is a Very Rare side effect. If symptoms such as abdominal pain, nausea, vomiting, or diarrhea occur after taking the tablet, contacting a healthcare professional is often advised.


Q: Are there any known issues with taking Candesartan Aurobindo before surgery?

Official documentation includes a warning that hypotension (low blood pressure) may occur during major surgery and anesthesia in patients taking this medication. This is a possibility due to the mechanism by which it blocks the renin-angiotensin system.


Q: Can Candesartan Aurobindo cause joint pain or muscle weakness?

The official regulatory side effect lists include back pain as a Common adverse reaction. Other less frequent, Very Rare side effects that have been reported include pain in joints and muscles.


Q: What if I experience flu-like symptoms after starting this medication?

Official patient information states that flu-like signs or symptoms and respiratory infection have been listed among the possible adverse reactions reported during clinical trials and post-marketing experience with the drug.


Q: Is it safe to take herbal supplements with Candesartan Aurobindo?

Authoritative guidance notes that there is very little information available regarding the safety of combining herbal remedies or other supplements with candesartan. It is generally advised to inform a doctor or pharmacist of all supplements being taken.


Q: Can Candesartan Aurobindo affect my balance or cause vertigo?

The list of common adverse reactions includes dizziness. Official side effect documentation also reports a spinning sensation (vertigo) as a potential, though less common, adverse effect.

How should Candesartan Aurobindo be stored and disposed of?

How to Store and Dispose of Candesartan Aurobindo

Candesartan Aurobindo tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept out of the reach of children to prevent accidental ingestion.


Stability and Handling

If a pharmacist prepares a liquid suspension, it must be stored at or below 30 C (86 F) and must not be frozen. This prepared suspension has an in-use shelf-life of 30 days after first opening.

Disposal Requirements

All unused or expired Candesartan product should be disposed of according to local regulations. It is required that the medication not be thrown away in wastewater or standard household waste to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candesartan Aurobindo found in:

A-Z Index: